Skip to main content
. Author manuscript; available in PMC: 2022 Mar 15.
Published in final edited form as: Nat Cancer. 2020 Jan 13;1(1):112–121. doi: 10.1038/s43018-019-0009-7

Extended Data Fig. 10 |. Prevalence of germline homologous recombination deficiency (HRD) proportion in European Americans (EAs) and African Americans (AAs) patients from the cancer Genome Atlas (TCGA) cohort.

Extended Data Fig. 10 |

Germline HRD (see methods) is quantified and presented in AAs and EAs for 17 cancer types with at least 30 AA samples in TCGA, where HRD is defined by 88 hallmark genes provided in Table S14, with the respective AA and EA patients included in each group. Refer here for reference to cancer types: https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations). Further, the number of samples in each group is provided in Table S12. AAs are shown in red and EAs in blue. A one-sided Fisher test was performed to test whether AA have higher germline HR-Deficiency than EA within each cancer types and the p-value is provided.